SEOUL — In a positive turn of events, SK Biopharmaceuticals Co. announced on Monday that it achieved a net profit of 7.8 billion won ($5.8 million) in the fourth quarter of 2023, a significant recovery from a loss of 43.9 billion won in the same period a year earlier. The company's operating income for the October-December quarter was reported at 15.2 billion won, marking a remarkable improvement from an operating loss of 44.6 billion won the previous year. Additionally, revenue during this quarter surged by 101.9 percent to 126.8 billion won.
According to Yonhap News Agency, the fourth quarter results indicate a noteworthy turnaround in its financial performance, demonstrating the company's capacity to overcome previous losses and generate profit.